US HB2087 | 2019-2020 | 116th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on April 4 2019 - 25% progression, died in chamber
Action: 2019-05-21 - Subcommittee Hearings Held.
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on April 4 2019 - 25% progression, died in chamber
Action: 2019-05-21 - Subcommittee Hearings Held.
Text: Latest bill text (Introduced) [PDF]
Summary
Requires certain manufacturers of drugs that are covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services. Specifically, manufacturers of such drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.
Title
Drug Price Transparency Act
Sponsors
Rep. Lloyd Doggett [D-TX] | Rep. Vern Buchanan [R-FL] |
History
Date | Chamber | Action |
---|---|---|
2019-05-21 | House | Subcommittee Hearings Held. |
2019-04-05 | House | Referred to the Subcommittee on Health. |
2019-04-04 | House | Referred to the Subcommittee on Health. |
2019-04-04 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2019-04-04 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2019-04-04 | House | Introduced in House |
Same As/Similar To
HB2113 (Related) 2020-12-24 - Placed on the Union Calendar, Calendar No. 571.
SB2051 (Related) 2019-06-28 - Read twice and referred to the Committee on Finance.
HB2296 (Related) 2019-09-24 - Placed on the Union Calendar, Calendar No. 170.
HB19 (Related) 2019-12-19 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
SB3129 (Related) 2019-12-19 - Read twice and referred to the Committee on Finance.
HB1570 (Related) 2020-12-10 - Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
SB2051 (Related) 2019-06-28 - Read twice and referred to the Committee on Finance.
HB2296 (Related) 2019-09-24 - Placed on the Union Calendar, Calendar No. 170.
HB19 (Related) 2019-12-19 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
SB3129 (Related) 2019-12-19 - Read twice and referred to the Committee on Finance.
HB1570 (Related) 2020-12-10 - Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
Administrative law and regulatory procedures
Civil actions and liability
Congressional oversight
Consumer affairs
Health
Health care costs and insurance
Health information and medical records
Insurance industry and regulation
Medicare
Prescription drugs
Retail and wholesale trades
Civil actions and liability
Congressional oversight
Consumer affairs
Health
Health care costs and insurance
Health information and medical records
Insurance industry and regulation
Medicare
Prescription drugs
Retail and wholesale trades
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/2087/all-info |
Text | https://www.congress.gov/116/bills/hr2087/BILLS-116hr2087ih.pdf |